EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Lidocaine Combined With Platelet‐Rich Plasma for Stellate Ganglion Block in Chronic Migraine: A Multicenter, Prospective, Propensity Score‐Matched Cohort Study

Lu Liu, Baolin Duan, Tao Ma, Long Li, Dong Yang, Fang Luo

Brain and Behavior · 2026

DOI: 10.1002/brb3.71736 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Brain and Behavior, 2026. Verfasst von Lu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Day Surgery Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Stellate Ganglion, Lidocaine, Migraine Disorders, Platelet-Rich Plasma. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Health Improvement and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To explore the association of stellate ganglion block with platelet‐rich plasma plus lidocaine with clinical outcomes in adults with chronic migraine, in comparison to lidocaine alone.

Methods

This multicenter prospective exploratory study enrolled 200 adults with chronic migraine scheduled for stellate ganglion block across three hospitals from October 2024 to September 2025. Treatment allocation was based on patient preference within a prespecified quota design, with 100 patients per group receiving either platelet‐rich plasma plus lidocaine or lidocaine alone. Propensity score matching was performed to balance confounders. The primary outcome was the mean change from baseline in monthly headache days at 1 month post‐intervention. Secondary outcomes included headache frequency, pain intensity, headache duration, response rate, analgesic consumption, functional status, and safety.

Results

After propensity score matching, 66 patients per group were analyzed. At one month, the platelet‐rich plasma plus lidocaine group showed a significantly greater reduction in monthly headache days compared with lidocaine alone (mean difference, 1.84 days; 95% confidence interval [CI], 0.68–2.99; p = 0.002). This advantage persisted at two and three months. The combination group also demonstrated superior improvements in pain intensity, headache duration, response rate, and analgesic reduction at all time points, along with better functional status at 1 and 2 months (all nominal P < 0.05). Baseline disability was a negative predictor of one‐month response. No significant differences in safety outcomes were observed.

Conclusion

In this exploratory study, stellate ganglion block with platelet‐rich plasma plus lidocaine was associated with clinically meaningful improvements in headache outcomes and functional status compared with lidocaine alone in patients with chronic migraine, with a favorable safety profile. These findings warrant validation in a definitive randomized trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stellate GanglionLidocaineMigraine DisordersPlatelet-Rich PlasmaAnesthetics, LocalAutonomic Nerve BlockHumansFemaleAdultMaleProspective StudiesMiddle AgedPropensity ScoreTreatment OutcomeChronic Disease

Stichwörter der Autor:innen

chronic migrainemonthly headache daysplatelet rich plasmastellate ganglion block

Substanzen

LidocaineAnesthetics, Local

Autor:innen und Institutionen

  • Department of Day Surgery Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Department Director of Pain Management, Suzhou Blue Cross Brain Hospital, Suzhou, Jiangsu, People's Republic of China.
  • Department of Pain Management, Qinghai Provincial People's Hospital, Xining, Qinghai, People's Republic of China.
  • Department of Pain Management, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Key Laboratory of Anesthesiology and Resuscitation (Huazhong University of Science and Technology), Ministry of Education, Wuhan, People's Republic of China.
  • Department of Pain Management and Day Care Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Förderung

  • National Key Research and Development Program of China
  • Health Improvement and Research

Zitieren

APA

Liu, L., Duan, B., Ma, T., Li, L., Yang, D., & Luo, F. (2026). Lidocaine Combined With Platelet‐Rich Plasma for Stellate Ganglion Block in Chronic Migraine: A Multicenter, Prospective, Propensity Score‐Matched Cohort Study. Brain and Behavior. https://doi.org/10.1002/brb3.71736

Vancouver

Liu L, Duan B, Ma T, Li L, Yang D, Luo F. Lidocaine Combined With Platelet‐Rich Plasma for Stellate Ganglion Block in Chronic Migraine: A Multicenter, Prospective, Propensity Score‐Matched Cohort Study. Brain and Behavior. 2026. doi:10.1002/brb3.71736

BibTeX
@article{Liu2026,
  author = {Liu, Lu and Duan, Baolin and Ma, Tao and Li, Long and Yang, Dong and Luo, Fang},
  title = {Lidocaine Combined With Platelet‐Rich Plasma for Stellate Ganglion Block in Chronic Migraine: A Multicenter, Prospective, Propensity Score‐Matched Cohort Study},
  journal = {Brain and Behavior},
  year = {2026},
  doi = {10.1002/brb3.71736}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche